Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174827 | 0.82 | CYP11B1 (0.43) | CYP11B1CYP11B2MGLLGAAGFER | |
| SCHEMBL21169218 | 0.76 | CYP1A2 (0.38) | GFERHSP90AA1HSP90AB1CYP1A2TDP1 | |
| SCHEMBL18806108 | 0.74 | CYP11B1 (0.43) | CYP11B1CYP11B2MGLLPDCD1LG2CD274 | |
| SCHEMBL23992153 | 0.73 | — | — | |
| SCHEMBL23992241 | 0.72 | MGLL (0.32) | CYP11B1CYP11B2MGLL | |
| SCHEMBL19226546 | 0.71 | CYP1A2 (0.42) | GAAHSP90AA1HSP90AB1CYP1A2TDP1 | |
| SCHEMBL19223939 | 0.69 | CYP1A2 (0.43) | GFERHSP90AA1HSP90AB1CYP1A2TDP1 | |
| SCHEMBL15447211 | 0.69 | DDB1 (0.47) | — | |
| SCHEMBL21201884 | 0.68 | CYP11B1 (0.42) | CYP11B1CYP11B2MGLLPDCD1LG2CD274 | |
| SCHEMBL24027743 | 0.68 | CYP1A2 (0.42) | GFERHSP90AA1HSP90AB1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | CYP11B1 2280/4885CYP11B2 2300/4885MGLL 4781/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | CYP11B1 2591/4885CYP11B2 2549/4885MGLL 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.